Sysmex (OTCMKTS:SSMXY) Sets New 12-Month Low - What's Next?

Key Points

• Sysmex Corporation's share price hit a new 52-week low of $12.22 before last trading at $12.41, reflecting a significant drop from its previous close.
• The company recently reported disappointing quarterly earnings, with an EPS of $0.05 that missed estimates by $0.07 and revenue of $717.09 million below expectations of $807.27 million.
• Zacks Research has upgraded Sysmex's rating from "strong sell" to "hold", although the overall consensus rating for the stock remains a "hold".

Sysmex Corporation ADR (OTCMKTS:SSMXY - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Friday . The company traded as low as $12.22 and last traded at $12.41, with a volume of 29785 shares. The stock had previously closed at $12.83.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Sysmex from a "strong sell" rating to a "hold" rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company has a consensus rating of "Hold".

Sysmex Trading Down 2.2%

The company's 50 day moving average price is $14.47 and its 200 day moving average price is $16.68. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.37 and a quick ratio of 2.49. The firm has a market cap of $7.90 billion, a PE ratio of 25.10 and a beta of 1.10.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). The company had revenue of $717.09 million for the quarter, compared to analysts' expectations of $807.27 million. Sysmex had a return on equity of 10.20% and a net margin of 9.35%. As a group, analysts forecast that Sysmex Corporation ADR will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.